DreamLite® ortho-k lenses by CooperVision SEC receive European approval for slowing myopia progression

Expanding the world’s largest portfolio of evidence-based myopia management interventions to give eye care professionals multiple options

Eerbeek, June 1, 2021 — DreamLite® night lenses by CooperVision Specialty EyeCare (SEC) have received the CE mark for slowing myopia progression in children and young adults. This popular orthokeratology contact lens already had a CE mark for the correction of myopia as a product and has now also received a CE mark for myopia management. This is in conjunction with MiSight® 1 day, CooperVision SEC’s soft day lens for myopia management.

CooperVision has the largest portfolio of evidence-based myopia management interventions worldwide. This gives eye care specialists multiple approved options for fighting the global myopia epidemic and provides them with support in tailoring the approach for each child and family.

Ron Beerten, Head of Professional Services EMEA: “It’s great that this CE mark for myopia management applies to the entire DreamLite® range. In doing so, we offer the opportunity for everyone to wear night lenses, which are proven to have a myopia-inhibiting effect.”

DreamLite® night lenses can be used for myopia management in children with a refraction of -0.75 D to -5.00 D and a cylindrical refraction with a maximum of -2.50 D. A two-year study showed that DreamLite® night lenses reduced axial length growth by 63% at high myopias compared to the control group of single lens eyeglasses – a total reduction of 0.32 mm.[1] The lenses are currently available in Europe, the Middle East and China.

Click here for the full English press release from CooperVision.

Read more about DreamLite®here.


About CooperVision Specialty EyeCare | CooperVision Specialty EyeCare (SEC) specializes in producing custom lenses with the highest precision and quality. The SEC division is part of the CooperVision organization, one of the world’s largest contact lens manufacturers with more than 10,000 employees. We sell our products in more than 100 countries, from China to Europe and from Africa to North and South America.
The SEC division focuses on innovative custom contact lenses to achieve optimal visual acuity for every person worldwide, regardless of the condition of the eye. By investing in our people and techniques on a daily basis, we are building our strength and future. The headquarters of the EMEA SEC division is located in Eerbeek. There, more than 110 employees are working on a common goal, which is to let everyone experience their world to the fullest.
For more information: www.procornea.nl

About CooperVision | CooperVision, part of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full range of daily lenses, biweekly lenses and soft monthly lenses, all featuring advanced materials and optics. CooperVision has a strong history of solving major vision problems, such as astigmatism, presbyopia and myopia in children; and it offers the most complete range of spherical, toric and multifocal products available. Through a combination of innovative products and targeted user support, the company offers an innovative perspective on the industry, creating real benefits for customers and users.
For more information, go to www.coopervision.com.

Note to editors: For more information, please contact Gabi Steenbekkers, Myopia Management Manager EMEA, 0031(0)313 677677.

[1] Charm J, Cho P. High myopia-partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci. 2013 Jun;90(6):530-9. doi: 10.1097/OPX.0b013e318293657d. PMID: 23645372.